Onyx Pharmaceuticals Inc. - Liver Disease Information

ONXX) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. In RCC ...